[go: up one dir, main page]

CR11631A - EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL - Google Patents

EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL

Info

Publication number
CR11631A
CR11631A CR11631A CR11631A CR11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A
Authority
CR
Costa Rica
Prior art keywords
paramyxovirus
human
antitumoral
effective
virus
Prior art date
Application number
CR11631A
Other languages
Spanish (es)
Inventor
Beier Rudolf
Puhler Florian
Original Assignee
Bayer Schering Pharma Ag
Grace Procurements Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Grace Procurements Llc filed Critical Bayer Schering Pharma Ag
Publication of CR11631A publication Critical patent/CR11631A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen paramyxovirus del grupo APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, virus Mapueray virus Fer-de-Lance, los cuales pueden ser usados para la produccion de un medicamento para el tratamiento de tumores. El virud tienhe la selectividad para matar celulas diferenciadas tumorales humanas pero no para matar celulas diferenciadas normales humanas o en proliferacion normal humanas con la misma dosis.Paramyxovirus of the group APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, Mapueray virus Fer-de-Lance virus, which can be used for the production of a medicament for the treatment of tumors are described. The virud has the selectivity to kill human tumor differentiated cells but not to kill normal human or normal proliferated human normalized cells with the same dose.

CR11631A 2008-02-14 2010-08-13 EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL CR11631A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075121 2008-02-14
US2965008P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
CR11631A true CR11631A (en) 2010-10-05

Family

ID=40955326

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11631A CR11631A (en) 2008-02-14 2010-08-13 EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL

Country Status (17)

Country Link
US (1) US20090208495A1 (en)
EP (1) EP2252307A2 (en)
JP (1) JP2011512344A (en)
KR (1) KR20100122482A (en)
CN (1) CN101945660A (en)
AU (1) AU2009214066A1 (en)
BR (1) BRPI0908365A2 (en)
CA (1) CA2715136A1 (en)
CO (1) CO6290694A2 (en)
CR (1) CR11631A (en)
DO (1) DOP2010000251A (en)
EA (1) EA201001266A1 (en)
EC (1) ECSP10010401A (en)
IL (1) IL206860A0 (en)
MX (1) MX2010008942A (en)
WO (1) WO2009101149A2 (en)
ZA (1) ZA201006561B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622087T3 (en) * 2009-08-21 2017-07-05 Merial, Inc. Recombinant vaccine against avian paramyxovirus and its manufacturing and use procedure
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
JP5603486B2 (en) * 2010-06-10 2014-10-08 インターベット インターナショナル ベー． フェー． Anti-tumor composition
WO2013112690A1 (en) * 2012-01-24 2013-08-01 Universtiy Of Georgia Research Foundation, Inc. Piv5 as oncolytic agent
RS63291B1 (en) 2013-09-03 2022-06-30 Medimmune Ltd COMPOSITIONS CONTAINING ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR THE TREATMENT OF NEOPLASIA
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
JP2021530501A (en) * 2018-07-13 2021-11-11 アイカーン スクール オブ メディシン アット マウント サイナイ APMV and its use for the treatment of cancer
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN115089591B (en) * 2022-05-21 2024-04-12 复旦大学 Application of brivanib in the preparation of drugs for inhibiting neurotropic enterovirus 71
CN116970650B (en) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 Envelope protein combination, targeting virus vector containing envelope protein combination and preparation method of targeting virus vector

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302278A3 (en) * 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
ATE451835T1 (en) * 1999-09-24 2010-01-15 Mayo Foundation THERAPEUTIC METHODS AND COMPOSITIONS USING VIRUSES OF THE RECOMBINANT FAMILY PARAMYXOVIRIDAE
EP1812026A2 (en) * 2004-11-12 2007-08-01 Schering Aktiengesellschaft Recombinant newcastle disease virus

Also Published As

Publication number Publication date
IL206860A0 (en) 2010-12-30
CO6290694A2 (en) 2011-06-20
US20090208495A1 (en) 2009-08-20
DOP2010000251A (en) 2010-08-31
MX2010008942A (en) 2010-09-07
ECSP10010401A (en) 2010-09-30
EA201001266A1 (en) 2011-04-29
JP2011512344A (en) 2011-04-21
ZA201006561B (en) 2012-02-29
AU2009214066A1 (en) 2009-08-20
WO2009101149A3 (en) 2009-11-05
CN101945660A (en) 2011-01-12
KR20100122482A (en) 2010-11-22
CA2715136A1 (en) 2009-08-20
WO2009101149A2 (en) 2009-08-20
EP2252307A2 (en) 2010-11-24
BRPI0908365A2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
CR11631A (en) EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL
CO2020003478A2 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and their uses
UY34750A (en) ? COMPOUNDS FOR HIV TREATMENT, COMPOSITIONS, PREPARATION METHODS, INTERMEDIARIES AND THERAPEUTIC METHODS ?.
CY1119058T1 (en) IMIDAZOPYRROLIDINONE COMPOUNDS
EA201591401A1 (en) SPIROLACTAM NMDA-RECEPTOR MODULATORS AND THEIR APPLICATION
DOP2015000300A (en) PYRIMIDINODIONA COMPOUNDS AGAINST HEART STATES
UY34566A (en) 1,4? DIHYDROPIRIMIDINES 4.4? DISUSTITUTED AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
UY34593A (en) APELINE SYNTHETIC MIMETICS FOR CARDIAC FAILURE TREATMENT
ECSP14017269A (en) COMPOUNDS TO TREAT SPINAL MUSCULAR ATROPHY
DOP2014000277A (en) COMPOUNDS AND COMPOSITIONS THAT MODULATE THE ACTIVITY OF THE EPIDERMAL GROWTH FACTOR RECEIVER (EGFR)
ECSP13012417A (en) NAPHT-2-ILACETIC ACID DERIVATIVES TO TREAT AIDS
AR092899A1 (en) USE OF MASITINIB FOR THE TREATMENT OF CANCER IN SUB-POPULATIONS OF IDENTIFIED PATIENTS USING PREDICTION FACTORS
BR112013020041A2 (en) compounds and methods for modulating kinases, and indications thereof
EA201591405A1 (en) SPIROLACTAM NMDA-RECEPTOR MODULATORS AND THEIR APPLICATION
SV2017005373A (en) INHIBITORS OF PROTEIN QUINASA C AND METHODS OF USE
ES2570958T3 (en) Composition for the treatment of fistula
CR20130377A (en) DRUG METHODS AND PRODUCTS TO TREAT ALZHEIMER'S DISEASE
CL2012003211A1 (en) Compounds derived from piperidinyl substituted lactams, modulators of gpr119; process to prepare the compounds; pharmaceutical composition comprising the compounds; and use of the compounds in the preparation of medicaments for the treatment or prevention of type 2 diabetes, obesity and related conditions
CL2019002900A1 (en) Benzoazepine analogs as bruton tyrosine kinase inhibitors.
GT201500071A (en) ANTIANDRÒGENOS FOR THE TREATMENT OF PROSTATE CANCER RESIDENT TO NON-METASTÀSIC CASTRATION3
EA201591987A1 (en) TREATMENT OF MALIGNANT TUMOR DIHYDROPYRAZINOPIRASINS
CL2017001275A1 (en) Linked urea analogs substituted as sirtuin modulators
ECSP12012354A (en) HETEROCYCLIC COMPOUNDS, ITS PREPARATION AND THERAPEUTIC APPLICATION
CL2013000310A1 (en) Compounds derived from disubstituted tetrahydrofuranyl and its salts, as antagonists of the b1 receptor of bradykinin; medicament containing said compounds; its preparation procedure, useful for the acute or prophylactic treatment of acute pain, osteoarthritis, asthma, allergies, among other diseases.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)